Note: Descriptions are shown in the official language in which they were submitted.
~3~7~
~:7F Al /~1 D~ 5 VI I
The present invention relates to peptides
having influence on the function of the pituitary gland
in humans and other animals. In particular, the present
invention is directed to a peptide which promotes the
release of growth hormone by the pituitary gland.
BACKGROUND OF rrHE INVENTION
Physiologists have long recognized that the
hypothalamus controls the secretory functions of the
adenohypophysis with the hypothalamus producing special
substances which stimulate or inhibit the secretion of
each pituitary hormone. A hypothalamic inhibitory
factor was characterized in 1972 in the form of
somatostatin which inhibits the secretion of growth
hormone(GH). In 1982, human pancreatic (tumor)
releasing factors (hpGRF) were isolated from extracts of
human pancreatic tumors, purified, characterized,
synthesized and tested, which were found to promote the
release of GH by the pituitary. Both of these
hypophysiotropic factors have been reproduced by total
synthesis, and analogs of the native structures have
been synthesized. Human hypothalamic GH releasing
factor has precisely the same structure; thus, the term
hGRF is used hereinafter.
SUMMARY OF THE INVENTION
Synthetic polypeptides have now been
synthesized and tested which release GH from cultured
pituitary cells, which have increased resistence to
enzymatic degradation in the body, and which exhibit
very substantially increased potency. It is believed
that these advantageous properties result from the
peptides having an alpha-helical form of increased
stability. These peptides preferably have at least one
residue in positions 10, 13, 19 and 22 that is
substituted with a methyl group on its alpha carbon atom
(CaMe), and most preferably several of these residues
are so substituted. D-Ala, N CH3-D-Ala(D-NMA) or
NMA may
3 ~
-- 2 --
be substituted in the 2-position. Either D-Lys or D~Arg
is preferably in the 21-position, and Nle is preferably
present in the 27-position. Lys is prefera~ly
substituted in the 8-position, but either Arg, Ser, Glu
or Asp may also be substituted. The peptides may also
have one of the following residues in the 1-position:
Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, Hi~ and
D-His, which res~due may optionally have a methyl
substitution either on the alpha-carbon or in the
alpha-amino group, or the alpha-amino group may be
deleted (desamino); this residue may also have its
alpha-amino group acylated, preferably by acetyl (Ac) or
formyl (For). The peptides may optionally have D-Asp at
the 3-position and/or Arg at the 12-position and/or Phe
or D-Tyr at the 10-position and/or Ala at the
15-position. They may also have D-Met or Nv~ or other
residues instead of Met in the 27-position and/or Asn in
the 28-position. The residues in the 13- and
~2-positions may be any of the following: Leu, Ile, Ala
and Val.
Pharmaceutical compositions in accordance with
the invention include such analogs which are between
about 29 and 44 residues in length, or a nontoxic salt
of any of these, dispersed in a pharmaceutically or
veterinarily acceptable liquid or solid carrier. Such
pharmaceutical compositions can be u~ed in clinical
medicine, both human and veterinary, for admunistration
for therapeutic purposes, and also diagnostically~
Moreover, they can be used to promote the growth of warm-
blooded animals, including fowl, and in aquiculture forcold-blooded animals, e.gO fish, eels, etc.
More particularly, the invention provides a
synthetic peptide, or a nontoxic salt
thereof, having the sequence: (B)R1-F~-R3-Ala-Ile-Phe-Thr-
R8-ser-R1o-Arg-R12-R13-Leu-R15-Gln-Leu-R18-Ala-Arg-R21
R24-R2s-Ile-R27-R2a-Arg-Gln-Gln-Gly-NH2 wherein Rt is Tyr, D-
Tyr, Met, D-Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His;
:`~.' . '5~,
- 2~ -
B is H, C~Me, N~Me, desamino, Ac or For: R2 i5 Ala, D-Ala,
NMA or D-NMA; R3 is Asp o.r D-Asp; R8 is Lys, Arg, Asp or
Glu; R10 is Tyr, D-Tyr, or Phe; R~z is Arg or Lys; R13 i5
Ile, Val, Leu or Ala; R15 is Gly or ~la; R18 is Ser or Tyr
R21 is Lys, D-Lys, Arg or D-Arg; R22 is Leu, Ile, Ala or
Val; R24 is Gln or His; R2s is Asp or Glu; R27 is Met, D-
Met, Ala, Nle, Ile, Leu, Nva or Val; R28 is Asn or Ser; or
an amidated fragment thereof which i5 at least 29
residues in length being shortened by the deletion of up
lQ to three residues beginning at the C-terminus.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The nomenclature used to define the peptides is
that specified by Schroder & Lubke, "The Peptides",
Academic Press (1965), wherein in accordance with
conventional representation the amino group at the
~C~2~
-- 3 --
N-terminus appears to the left and the carboxyl group at
the C-terminus to the right. By natural amino acid is
meant one of common, naturally occurring amino acids
found in proteins comprising Gly, Ala, Val, Leu, Ile,
Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cy5, Met, Phe,
Tyr, Pro, Trp and His. By Nle is meant norleucine, and
by Nva is meant norvaline. Where the amino acid residue
has isomeric formsr it is the L-form of the amino acid
that is represented unless otherwise expressly indicated.
D-NMA signifies the D-isomer of alanine wherein the
alpha-amino group is subtituted by methyl.
The invention generally provides synthetic
peptides having the following sequence (I): (B) Rl-R2-R3-
Ala-Ile-phe-Thr-R8-ser-(Ql)Rlo Arg R12 (Q2) Rl3
Rl5_Gln_LeU-Rl8- (Q3) Ala-Arg R21 (Q4)R22 24
R25-Ile-R27-R28-Arg-Gln-Gln-Gly-Glu-R34-Asn-Gln-Glu-R38-
39 R40 Arg R42 R43 R44 wherein Rl is Tyr, D-~yr, Met,
Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, C Me,
NaMe, desa~ino, Ac or For; R2 iS Ala, D-Ala, NMA or
D-NMA; R3 is Asp or D-Asp; R8 is Ser, Asn, Lys, Arg,
Asp or Gln; Rlo is Tyr, D-Tyr or Phe, R12 is Arg or
Lys; R13 is Ile, Val, Leu or Ala; R15 is Gly or Ala;
R18 is Ser or Tyr; R21 is Lys, D-Lysl Arg or D-Arg;
R22 is Leu, Ile, Ala or Val; R24 is Gln or His;
R25 is Asp or Glu; R27 is Met, D-Met, Ala~ Nle, Ile,
Leu, Nva or Val; R28 is Asn or Ser; R34 is Ser or
Arg; R38 is Arg or Gln; R39 is Gly or Arg; R40 is
Ala or Ser; R42 is Phe, Ala or Val; R43 is Asn or
Arg; R44 iS a natural amino acid; 1-Q4 are either
30 H or CaMe, provided however that any or all of the
residues between R30 and R44, inclusive, may be
deleted, and provided also that at least one of Ql-Q4
is CaMe and/or R8 is Lys or Arg and/or R21 is D-Lys
or D-Arg.
Preferably the peptides should have the sequence:
(B) Rl-R2-R3-Ala-Ile-Phe-Thr-R8-Ser- (Ql) RlO-Arg-Rl2-
(Q2 )R13-Leu-R15-Gln-Leu-Ser-(Q3) Ala-Arg-R21-(Q~)R22-
-- 4 --
27 R28-Arg~Gln-Gln-Gly-Glu-Ser As Gl
Glu-Arg-Gly-Ala-Arg-R~2-R43-R44 wherein Rl is Tyr,
D-Tyr, Met, Phe, D-Phe, pCl-Phe, 1eu, His or D-His; B is
H, CaMe, NaMe, desamino, Ac or For; R2 is Ala,
D-Ala, NMA or D-NMA; R3 is Asp or D-Asp; R8 is Ser,
Asn, Lys, Arg, Asp or Gln; Rlo is Tyr, D-Tyr or Phe;
Rl2 is Arg or ~ys; Rl3 is Ile, Val, Leu or Ala;
Rl5 is Gly or Ala; R2l is Lys, D-Lys, Arg or D-Arg;
R22 is Leu, Ile, Ala or Val; R27 is Met, D-Met, Ala,
Nle, Ile, Leu, Nva or Val; R2~ is Asn or Ser; R42 is
Phe, Ala or Val; R43 is Asn or Arg; R44 is a natural
amino acid; Ql-Q4 are either H or CaMe, provided
however that any or all of the residues between R30
and R44, inclusive, may be deleted. Preferably at
least one of Ql-Q4 is CaMe; preferably R8 is Lys
or Arg; and preferably R2l is D-Lys or D-Arg. The
carboxyl moiety of the amino acid residue at the
C-terminus may be any of the follow;ng radicals:
-COOR,-CRO,-CONHN~R,-CON(R)(R') or -CH2OR, with R and
R' being lower alkyl, fluoro lower alkyl or hydrogen;
methyl, ethyl and propyl are the preferred lower alkyl
groups. When Met appears in position l, it may be
preferable to have another residue in position 27~
Fragments which extend from the N-terminus
~5 through residue-29 have biological potency in effecting
the release of GH by the pituitary, and biologically
active fraqments of 29 or 32 residues in length which
have a C-terminus that is an amide or a substituted
amide are most preferred. When the peptide has 40 or
more residues, there is no clear preference for the
moiety at the C-terminus.
The peptides are synthesi~ed by a suitable
method, such as by exclusively solid-phase techniques,
by partial solid-phase techniques, by fragment
3~ condensation or by classical solution couplings. The
employment of recently developed recombinant DNA
techniques may be used to prepare a portion of an analog
containing only natural amino acid residues, which could
then be linked to a short N-terminal peptide. For
example, techniques of exclusively solid-phase synthesis
are set forth in the textbook "Solid-Phase Peptide
Synthesis", Stewart & Young, Freeman & Co., San
Francisco, 1969, and are exemplified by the disclosure
of U.S. Patent No. 4,105,503, issued August 8, 1978 to
Vale et al. Classical solution synthesis is described
in detail in the treatise "Methoden der Organischen
Chemie (Houben-Weyl): Synthese von Peptiden", E. Wunsch
(editor) (1974) Georg Thieme Verlag, Stuttgart, W. Ger.
The fragment condensation method of synthesis is
exemplified in U.S. Patent No. 3,972,859 (August 3,
1976). Other available syntheses are exemplified by
U.S. Patent No. 3,842,067 (October 15, 1974) and U.S.
Patent No. 3,862,925 (January 28, 1975).
Common to such syntheses is the protection of
the labile side chain groups of the various amino acid
moieties with suitable protecting groups which will
prevent a chemical reaction from occurring at that site
until the group is ultimately removed. Usually also
common is the protection of an alpha-amino group on an
amino acid or a fragment while that entity reacts at the
carboxyl group, followed by the selective removal of the
alpha-amino protecting group to allo~ subsequent
reaction to take place at that location. Accordingly,
it is common that, as a step in the synthesis, an
intermediate compound is produced which includes each of
the amino acid residues located in its desired sequence
in the peptide chain with side-chain protecting groups
linked to the appropriate residues.
In this respect, the present invention creates
intermediates of the Formula (II): Xl-(B)Rl(X or X2)-
R2-R3(X )-Ala-Ile-Phe-Thr(X )-R8(X33 Ser(X4)-R10(X )-
Ar9(X )-R12(X or X )-(Q2)R13 Le7u R15 15
(x2)-(Q3)Ala-Arg(x6)-R2l(x or X )-(Q4)R22-LeU~R2~(x
or X)-R25(X )-Ile-R27-R28~X4 or X5)-Arg(X )-Gln(X )-
~3 . . ~ ~ J
-- 6 --Gln(X5~-Gly-Glu(X3)-R34(X4 or X6) Asn(X5)-Gln(X5)-Glu
(X3)-R38(X6 or X5)-R~9(X6)-R40(X2)-Arg(X6)-R42-R~3
(X5 or X6)-R4~(X8)-X wherein: Xl is either hydrogen
or an a-amino protecting group. The a-amino protecting
groups contemplated by Xl are those well known to be
useful in the art of stepwise synthesis of polypeptides.
Among the classes of a-amino protecting groups which may
be employed as Xl are (1) aromatic urethan type pro-
tecting groups, such as fluorenylmethyloxycarbonyl
(FMOC), benzyloxycarbonyl(Z) and substituted Z, such as
p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl,
p-bromobenzyloxycarbonyl, and p-methoxybenæyloxycar-
bonyl; (2) aliphatic urethan protecting groups, such as
t-butyloxycarbonyl IBOC), diisopropylmethyloxycarbonyl,
isopropyloxycarbonyl, ethoxycarbonyl, allyloxycarbonyl;
and (3) cycloalkyl urethan-type protecting groups, such
as cyclopentyloxycarbonyl, adamantyloxycarbonyl,and
cyclohexyloxycarbonyl. The preferred a-amino protecting
group is BOC, even when an NaMe-substituted residue is
employed in the l-position; of course Xl is H when B
is desamino.
X is hydrogen or a protecting group for the
imidazole nitxogen of His, such as Tos.
x2 may be a suitable protecting group for the
phenolic hydroxyl group of Tyr, such as
tetrahydropyranyl, tert-butyl, trityl, Bzl, CBZ, 4Br-CBZ
and 2,6-dichlorobenzyltDCB). The preferred protecting
group is 2,6-dichlorobenzyl. X can be hydrogen which
means that there is no side-chain protecting group on
the amino acid residue in that position.
X3 is hydrogen or a suitable ester-forming
protecting group for the carboxyl group of Asp or Glu,
such as kenzyl(OBzl), 2,S-dichlorobenzyl, methyl and
ethyl.
X4 may be a suitable protecting group for the
hydroxyl group of Thr or Ser, such as acetyl, benzoyl,
tert-butyl, trityl, tetrahydropyranyl, Bzl, 2,S-dichloro-
11,C~ 3 1
-- 7 --
benzyl and CBZ. The preferred protecting group is Bzl.
X can be hydrogen, which means there is no protecting
group on the hydrox~l group.
X5 is hydrogen or a suitable protecting group
for the side chain amido group of Asn or Gln. It is
preferably xanthyl(Xan).
x6 is a suitable protecting group for the
guanido group of Arg, such as nitro, Tos, CBZ,
adamantyloxycarbonyl, and BOC, or is hydrogen.
X7 is hydrogen or a suitable protecting group
for the side chain amino group of Lys. Illustrative of
suitable side chain amino protecting groups are
2-chlorobenzyloxycarbonyl(2-Cl-Z), Tos, t-amyloxycarbonyl
and BOC.
xB is hydrogen or a suitable side-chain
protecting group as generally specified above.
Met can optionally be protected by oxygen, but
is preferably left unprotected.
The selection of a side chain amino protecting
group is not critical except that generally one is
chosen which is not removed during deprotection of the
a-amino groups during the synthesis. However, for some
amino acids, e.g. His, protection is not generally
necessary after coupling is completed, and the
protecting groups may be the same.
X9 is a suitable protecting group for the
C-terminal carboxyl group, such as the ester-forming
~roup X3, or is an anchorin~ bond used in solid-phase
synthesis for linking to a solid resin support, or is
des-X9, in which case the residue at the C-terminal
has a carboxyl moiety which is Y, as defined herein-
before. When a solid resin support is used, it may be
any of those known in the art, such as one having the
formulae: -O-CH2-resin support, -NH-benzhydrylamine
~BMA) resin support or -NH-paramethylbenzhydrylamine
(MBHA) resin support. When the unsubstituted amide is
desired, use of BHA or MBHA resin is preferred, because
~3~2~
-- 8 --
cleavage directly gives the amide. In case the N-methyl
amide is desired, it can be generated from an N-methyl
BHA resin. Should other substituted amides be desired,
the teaching of U.S. Patent No. 4,569,967 can be used,
or should still other groups than the free acid be
! desired at the C-terminus, it may be preferable to
sythesize the peptide using classical methods as set
forth in the Houben-Weyl text.
In the ~ormula for the intermediate, at least
one of the X-groups is a protecting group or X9
includes resin support. Thus, the invention also
provides a method ~or manufacturing a peptide of
interest by (a) forming a peptide having at least one
protective group and the formula (I~): wherein: X,
Xl, X2, X3, X4, X5, X6, X7 and X~ are each either
hydrogen or a protective group and X9 is either a
protective group or an anchoring bond to resin support
or is des-X9, in which case the residue at the
C-terminus may have the desired carboxy moiety;
(b) splitting off the protective group or groups or
anchoring bond from the peptide of the formula (II); and
(c) if desired, converting the resulting peptide of the
sequence rI) into a nontoxic salt thereof.
In selecting a particular side chain protecting
group to be used in the synthesis of the peptides, the
followin~ general rules are followed. (a) the protecting
group preferably retains its protecting properties and
is not be split off under coupling conditions, (b) the
protecting group should be stable to the reagent and,
with the e~ception of Xan, is preferably stable under
the reaction conditions selected for removing the
a-amino protecting group at each step of the synthesis,
and (c) the side chain protecting group must be
removable, upon the completion of the synthesis
~ 35 containing the desired amino acid sequence, under
; reaction conditions that will not undesirably alter the
~ peptide chain.
3 ~
g
When peptides are not prepared using recombinant
DNA technology, they are preferably prepared using solid
phase synthesis, such as that generally described by
Merrifield, J. Am. Chem. Soc., 85, p 2149 (1963),
although other equivalent chemical syntheses known in
the art can also be used as previously mentioned.
Solid-phase synthesis is commenced from the C-terminus
of the peptide by coupling a protected a-amino acid to a
suitable resin. Such a starting material can be
prepared by attaching an a-amino-protected amino acid by
an ester linkage to a chloromethylated resin or a
hydroxymethyl resin, or by an amide bond to a BHA resin
or MBHA resin. The preparation of the hydroxymethyl
resin is described by Bodansky et al., Chem. Ind.
(London) 38, 1597-98 (1956~. Chloromethylated resins
are commercially available from Bio Rad Laboratories,
Richmond, California and from Lab. Systems, Inc. The
preparation of such a resin is described by Stewart et
al., "Solid Phase Peptide Synthesis" (Freeman & Co., San
~0 Francisco 1969), Chapter 1, pp 1-6. BHA and MBHA resin
supports are commercially available and are generally
used only when the desired polypeptide being synthesized
has an unsubstituted amide at the C-terminal.
The C terminal amino acid, e.g. Asn, protected
by BOC and by Xan, can be first coupled to the
chloromethylated resin according to the procedure set
forth in Chemistry Letters, K. Horiki et al. 165-168
(1978), using KF in DMF at about 60C. for 24 hours with
stirring, when for example a 43-residue free acid analog
of ratGRF kGRF) is to be synthesized. Following the
coupling of ~he BOC-protected amino acid to the resin
support, the a-amino protecting group is removed, as by
using trifluoroacetic acid(TFA) in methylene chloride or
TFA alone. The deprotection is carried out at a
temperature between about 0C and room temperature.
Other standard cleaving reagents, such as HCl in
dioxane, and conditions for removal of specific a-amino
~D 3
-- 10 --
protecting gxoups may be used as described in Schroder &
Lubke, "The Peptides", 1 pp 72-75 (Academic Press 1965).
After removal of the a amino protecting group,
the remaining a-amino- and side chain~protected amino
acids are coupled step-wise in the desired order to
obtain the intermediate compound defined hereinbefore,
or as an alternative to addiny each amino acid
separately in the synthesis, some of them may be coupled
to one another prior to addition to the solid phase
reactor~ The selection of an appropriate coupling
reagent is within the skill of the art. Particularly
suitable as a coupling reagent is N,N'-dicyclohexyl
carbodiimide tDCCI).
The activating reagents used in the solid phase
synthesis of the peptides are well known in the peptide
art. Examples of suitable activating reagents are
carbodiimides, such as N,N'-diisopropylcarbodiimide and
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide. Other
activating reagents and their use in peptide coupling
are described by Schroder & Lubke supra, in Chapter III
and by Kapoor, J~ Phar. Sci., 59, pp 1 27 (1970).
~ ach protected amino acid or amino acid
sequence is introduced into the solid phase reactor in
about a fourfold or more excess, and the coupling may be
carried out in a medium of dimethylformamide(DMF):
CH2C12 (1:1) or in DMF or CH2C12 alone. In
cases where incomplete coupling occurs, the coupling
procedure i5 repeated before removal of the a-amino
protecting group prior to the coupling of the next amino
3~ acid. The success of the coupling reaction at each
stage of the synthesis, if performed manually, is
preferably monitored by the ninhydrin reaction, as
described by E. Kaiser et al., Anal. Biochem. 34, 595
(1970). The coupling reactions can be performed
automatically, as on a Beckman 990 automatic
synthesizer, using a program such as that reported in
Rivier et al. Biopolymers, 1978r 17, pp 1927-1938.
~3:L~si'~311
After the desired amino acid sequence has been
completed, the intermediate peptide can be removed from
the resin support by treatment with a reagent, such as
liquid hydrogen fluoride, which not only cleaves the
peptide from the resin but also cleaves all remaining
side chain protecting groups X, X2, X3, X4, X5,
X6, X7 and x8 and the anchoring bond ~9 and also
the a-amino protecting group ~1 if one is used, to
obtain the peptide in the form of the free acid. If Met
10 i5 present in the sequence, the BOC protecting group is
preferably first removed using trifluoroacetic
acid(TFA)/ethanedithiol prior to cleaving the peptide
from the resin with HF to eliminate potential
S-alkylation. When using hydrogen fluoride for
cleaving, anisole and methylethyl sulfide are included
as scavengers in the reaction vessel.
The following Example I sets forth a preferred
method for synthesizing peptides by the solid-phase
technique. It will of course be appreciated that the
synthesis of a correspondingly longer peptide is
effected in the same manner by merely adding the
requisite number of amino acids at the C terminus of the
chain. It is presently felt that biologically active
fragments should contain the indicated sequence at the
N-terminus, and addition of residues to the N-terminus
is not considered advantageous.
~ 3 L 2 1 ~ ~
- 12 -
EXAMPLE I
The synthesis of the peptide [NaMeTyrlr
Asp3, Alal5~ Nle27, Asn2~]-hGRF(1-29)-NH2
having the formula: NaMeTyr-Ala-Asp-Ala-Ile-Phe-Thr-
Asp-Ser-Tyr-Arg~Lys-Val-Leu-A:La-Gln-Leu-Ser-Ala-Arg-Lys-
Leu-Leu-Gln-Asp-Ile-Nle-Asn-Arg-NH2 is conducted in a
stepwise manner using a Beckman 990 peptide synthesizer
on a commercially available MBHA resin as generally
described in Vale et al. U.S. Patent No. 4,292,313.
Coupling of BOC-Arg(Tos) to the resin results in the
substitution of about 0.35 mmol. Arg per gram of resin.
After deblocking and neutralization, the
peptide chain is built step-by-step on the resin.
Deblocking, neutralization and addition of each amino
acid is performed in general accordance with the
procedure set forth in detail in Rivier, J, J. Amer.
Chem. Soc., 96, 2986-~992 (1974). All solvents that are
used are carefully degassed by sparging with an inert
gas, e.g. helium or nitrogen, to insure the absence of
oxygen that might undesirably oxidize the sulfur of the
Met residue.
Deblocking is preferably carried out in
accordance with Schedule A which follows:
SCHEDULE A
Reagent Mixing time (Min.
1. 60% TFA/2% ethanedithiol 10
2. 60% TFA/2~ ethanedithiol 15
3. IPA/l~ ethanedithiol 0O5
4- Et3N (10%) in CH2C12 0.5
5. MeOH 0.5
6- Et3N (10%) in CH2C12 0.~
7. MeOH (twice) 0.5
8. CH2C12 (twice) 0.5
The couplings are preferably carried out as set out
in Schedule B which follows:
~2 ~1
- 13 -
SCHEDULE B
Reagent Mixin~_time (Min.)
9. DCCI
10. Boc-amino acid 50-90
ll. MeOH (twice) 0.5
12. CH2C12 (twice) 0.5
13- Ac2O (3M) in CH2C12 15.0
14- CH2C12 0 5
15. MeOH 0.5
16. CH2C12 (twice~ 0 5
Briefly, one to two mmol. of BOC-protected
amino acid in methylene chloride is used per gram of
resin, plus one equivalent of 1~0 molar DCCI in
methylene chloride for two hours. When BOC-Arg(Tos) is
being coupled, a mixture of 50% DMF and methylene
chloride is used. B~l ether is used as the hydroxyl
side-chain protecting group for Ser and Thr. The amido
group of Asn or Gln is protected by Xan when DCC
coupling is us~d as is preferred. P-nitrophenyl
ester(ONp) may also be used to activate the carboxyl end
of Asn or Gln, and for example, BOC-Asn(ONp) can be
coupled overnight using one equivalent of HOBt in a 50~
mixture o~ DMF and methylene chloride, in which case no
DCC is added. 2-chlo~o-benzyloxycarbonyl(2Cl-Z) is used
as ~he prote~ting group for the Lys side chain. Tos is
used to protect the guanido group of Arg and the
imidazo~e nitrogen of His, and the Glu or Asp side-chain
carboxyl group is protected ~ith OBzl. The phenolic
hydroxyl group of Tyr is protected with 2,6-dichloro-
benzyl(DCB~. At the end of the synthesis, the followingcomposition is obtained:BOC-N MeTyr~X )-Ala-Asp(X 3-Ala-Ile-Phe-Thr(X ~-Asp(X )-
Ser(X4)~Tyr~X2)-Arg(X6)-Lys(X7)-Val-Leu-Ala-Gln(X5)-
Leu-SerlX4l-Ala-Ar~(X5)-Lys~X7)-Leu-Leu-Gln(X5)-Asp~X3)-
Ile-Nle-Asn(X )-Ar~(X )-X9 wherein X is DCB~
X3 is OBzl, X4 is Bzl, X5 is Xan, X~ is Tos,
X7 is 2Cl-Z and X9 is NH-MBHA-resin support. Xan
U ~ G,)'!i~
may have been partially or totally removed by TFA
treatment used to deblock the a-amino protecting group.
In order to cleave and deprotect the protected
peptide-resin, it is treated with 1.5 ml. anisole, 0.5
ml. methylethylsulfide and 15 ml. hydrogen fluoride(HF)
per gram of peptide-resin, at -20C. for one-half hour
and at 0.C. for one~half hour. After elimination of
the F under high vacuum, the resin-peptide remainder is
washed alternately with dry diethyl ether and
chloroform, and the peptide is then extracted with
degassed 2N aqueous acetic acid and separated from the
resin by filtration.
The cleaved and deprotected peptide is then
dissolved in 0-5~ acetic acid and subjected to
purification which may include Sephadex*G-50 fine gel
filtration.
The peptide is then further purified by
preparative or semi-preparative HPLC as described in
Rivier et al., PePtides: Structure and Biological
Function, ~1979) pp 125-8 and Marki et al. J. Am. Chem.
Soc. 103, 3178 (1981~. Cartridges f-itting Waters
Associates prep LC-500 are packed with 15-20u C18
Silica from Vydac*(300A). A gradient of C~3CN in TEAP
is generated by a low pressure Eldex gradient maker, as
described in Rivier, J., ~. Liq~ Chromato~raphy 1,
343-367 (1978). The chromatographic fractions are
carefully monitored by HPLC, and only the fractions
showing substantial purity are pooledO Desalting of the
purified fractions, independently checked for purity, is
achieved using a gradient of CH3CN in 0.1% TFA. The
center cut is then lyophilized to yield the desired
peptide, the purity of which can be greater than 98%.
EXAMPLE II
The synthesis of a 40-residue amidated peptide
[CaMeHisl, D-NMA2, D-Lys21]-hGRF(1-40)-NH2
having the formula: H-CaMeHis-D-NMA-Asp-Ala-Ile-
Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-
;.. ~,
~ * trade-mark
,.i
~ 3~
Ser-Ala-Arg-D-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-
Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg Gly-Ala-NH2 is
conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MB~IA resin as generally
described in Vale et al. U.S. Patent No. 4,292,313. The
peptide is judged to be substantially pure using TLC and
HPLC.
EXAMPLE III
The synthesis of ED-NMA , D~Lys 1, Nle 7]-
rGRF(1~43) OH having the formula: H-His D-NMA-Asp-Ala-
Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-
Ala-Arg-D-Lys-Leu-Leu-His-Glu-Ile-Nle-Asn-Arg-Gln-Gln-
Gly-Glu-Arg-Asn-Gln-Glu-Gln-Arg-Ser-Arg-Phe-Asn-OH is
conducted in a stepwise manner using a Beckman*9~0
Peptide Synthesizer, using a chloromethylated resin with
initial coupling as described in Chemistry Letters,
supra, and thereafter in the manner generally described
in Example I. The peptide is judged to be substantially
pure using TLC and HPLC.
EXAMPLE IV
The synthesis of the hGRF analog fragment,
a Ty 1 LyS8 Alal5 Nle27, ~Sn28l-hGRF(l-29)-NH2
having the formula: NaMeTyr-Ala-Asp-Ala-Ile-
Phe-Thr-Lys-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-
Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Asn-Arg-NH2 is
conducted in a stepwise manner using a Beckman 990
Peptide Synthesizer on an MBHA resin as in Example I.
This analog is judged to be substantially pure using TLC
and HPLCo
The synthesis is repeated changing the
N-terminal residue to produce [NaMeHisl, Lys , Ala
Nle27, Asn~8]-hGRF(1-29)-NH2
EXAMPLE V
- The synthesis of the hGRF analog fragment
35 [NaMeTyrl, D-Lys21, Nle27]-hGRF(1-29)-NH2 having the
formula: N MeTyr-Ala-Asp-Ala~Ile-Phe-Thr-Asn-Ser-Tyr-
Arg-Lys-Val--Leu Gly-Gln-Leu-Ser-Ala-Arg-D-Lys-Leu-Leu-
. * trade-mark
., `.!
:~ 3 ~
16 -
Gln-Asp-Ile-Nle-Ser Arg-NH2 is conducted in a stepwise
manner using a Beckman*990 Peptide Synthesizer on an
MBHA resin as in Example I. The peptide is judged to be
substantially pure using TLC and HPLC.
EXAMPI,E VI
The synthesis of [NaMeHisl, D-NMA2, Lys8,
D-Arg21, Nle27]-rGRF(1-29)-NH2, having the formula:
NaMe-His-D-MMA-Asp-Ala-Ile-Phe-Thr-Lys-Ser-Tyr-Arg-Arg-
Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-D-Arg-Leu-l.eu-His-Glu-
Ile-Nle-Asn-Arg-NH2 is conducted in a stepwise manner
using a Beckman 990 Peptide Synthesizer on an MBHA resin
as in Example I. The peptide is judged to be substanti-
ally pure using TLC and HPLC.
EXAMPLE VII
The synthesis of [NaMeTyrl, D-Tyr10, D-Lys lt
Nle27]-hGRF(1-29~-NH2 having the formula: NaMeTyr-
Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-D-Tyr-Arg-Lys-Val-Leu-
Gly-Gln-Leu-Ser-Ala-Arg-D-Lys-Leu-Leu-Gln-Asp-Ile-Nle-
Ser-Arg-NH2 is conducted in a stepwise manner using a
Beckman*990 Peptide Synthesiæer on an MBHA resin as in
Example I. The peptide is judged to be substantially
pure using TLC and HPLC.
EXAMPLE VIII
The synthesis of lD N~A2, Asp8, D-Lys~l,
Nva27]-rGRF~1-29~-NH2 having the formula: H-His-
D-NMA-Asp-Ala-Ile-Phe-Thr-Asp-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-
Gln-Leu-Tyr-Ala-Arg-D-Lys-Leu-Leu-His-Glu-Ile-Nva-Asn-Arg-
NH2 is conducted in a stepwise manner using a Beckman*
~90 Peptide Synthesizer on an MBHA resin as in Example
I. The peptide is judged to be substantially pure using
TLC and HPLC.
EXAMPLE IX
The synthesis of lD-Phe , D-NMA , Glu8,
CaMeTyr10, Xlel3, D-Lys21]-hGRF(1-32)-NH2 having the
formula:
H-D-Phe-D-NMA-Asp-Ala-Ile-Phe-Thr-Glu-Ser-CaMeTyr-Arg-
~,'5' Lys-Ile-Leu-Gly-Gln-Leu-Ser-Ala-Arg-D-Lys-Leu-Leu-Gln-Asp-
,;,
.. ..
* trade-mark
~ 3 ~ C~
Ile-Met-Ser-Arg-Gln-Gln-Gly-NH2 is conducted in a
stepwise manner using a Beckman*990 Peptide Synthesizer
on an MBHA resin as generally described in Vale et al.
U.S. Patent No. 4,292,313. The peptide is judged to be
substantially pure using TLC and HPLC.
EXAMPLE X
The synthesis of lpCl-Phel, D-NMA2,
D LyS21 ~al22 Asp25, Ile27]-rGRF(l-29)-NH2
having the formula: ~-pCl-Phe-D-NMA-Asp-Ala-Ile-Phe-
Thr-Ser-Ser-Tyr-Arg Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-
D-Lys-Val-Leu-His-Asp-Ile-Ile-Asn-Arg-NH2 is conducted
in a stepwise manner using a B~eckman*990 Peptide
Synthesizer on an MBHA resin, in the manner generally
described in Example I. The peptide is judged to be
5 substantially pure using TLC and HPLC.
EXAMPLE XI
The synthesis of ECaMeLeul, D-NMA2, D-Asp3,
Lys8, D-Lys21, Ala22]-hGRF(1-32)-NH2 having the
formula: H-CaMeLeu-D-NMA-D-Asp-Ala-Ile-Phe-Thr-Lys-
Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-D-Lys-
Ala-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-NH2 iS
conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as in Example I.
This analog is judged to be substantially pure using TLC
and HPLC.
EXAMPLE XII
The synthesis of [D-Tyrl, D-NMA2, D-Asp3,
caMe D TyrlO AlalS, D-Arg21, caMeval22~ D-Met ]-
hGRF~1-29~-NH2 having the formula: H-D-Tyr-D-NMA-
D-Asp-Ala-Ile-Phe-Thr-Asn-Ser-CaMe-D-Tyr-Arg-Lys-Val-
Leu-Ala-Gln-Leu-Ser-Ala-Arg-D-Arg-CaMeVal-Leu-Gln-Asp-
Ile-D-Met-Ser-Arg-NH2 is conducted in a stepwise
manner using a Beckman*990 Peptide Synthesizer on an
MBHA resin as in Example I. This analog is judged to be
substantially pure using TLC and HPLC.
EXAMPLE XIII
The synthesis of ED-Hisl, D-NMA2, Lys8,
* trade-mark
, /r,3 ~
13 L 21 Ala27l-rGRF(l-29) NH2
formula: H-D-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Lys-Ser-Tyr-
Arg-Arg-Leu-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-D-Lys-Leu-Leu-His-
Glu-Ile-Ala-Asn-Arg-NH2 is conducted in a stepwise
manner using a Beckman*990 Peptide Synthesizer on an MBHA
resin, in the manner generally described in Example I.
The peptide is judged to be substantially pure using TLC
and HPLC.
EXAMPLE: XIV
The synthesis of a rGRF analog fragment i.e.
~N MeTyr , D-NMA2, Glu8, Ala13 D_Arg21 caM Il 22]
rGRF(1-29)-NH2 having the formula: NaMeTyr-D-NMA-
Asp-Ala-Ile-Phe-Thr-Glu-Ser-Tyr-Arg-Arg-Ala-I,eu-Gly-Gln-
Leu-Tyr-Ala-Arg-D-Arg-CaMeIle-Leu-His-Glu-Ile-Met-Asn-
Arg-NH2 is conducted in a stepwise manner using a
Beckman*9~0 Peptide Synthesizer on an MBHA resin as in
Example I. The peptide is judged to be substantially
pure using TLC and HPLC.
EXAMPLE XV
The synthesis of lCaMeLeul, D-NMA2, Leu 3,
caMeA~al9 D_Lys2l, CaMeAla22, Ala ]-rGRF~ 9)
NH2 having the formula: H-CaMeLeu-D-NMA-Asp-Ala-Ile-
Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Leu-Leu-Gly-Gln-Leu~Tyr-
CaMeAla-Arg-D-Lys-CaMeAla~Leu-His-Glu-Ile-Ala-Asn-
Arg-NH2 is conducted in a stepwise manner using a
Beckman 990 Peptide Synthesizer on an MBMA resin as in
Example I. The peptide is judged to be substantially
pure using TLC and HPLC.
EXAMPLE XVI
The synthesis of [CaMePhel, NMA , Lys8, Argl2,
Ilel3~ CaMeAlal9, Ile27~-hGRF~1-29)-NH2 having
the formula: H-CaMePhe -NMA-Asp-Ala-Ile-Phe-Thr-Lys-
Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Ser-CaMeAla-Arg-Lys-
Leu-Leu-Gln-Asp-Ile-Ile-Ser-Arg NH2 is conducted in a
stepwise manner using a Beckman*590 Peptide Synthesizer
on an MBHA resin as generally described in Vale et alD
U.S. Patent No. 4,292~313. The peptide is judged to be
.~ *'trade-mark
- 19
substantially pure using TLC and HPLC.
EXAMPLE XVII
The synthesis of [desaminoD-Tyr1, D-NMA2,
A~g ,Phe , CaMevall3, ~eu27 Asn28] hGRF
~1-29)-NH2 having the formula: desNH2-D-Tyr-D-NMA-
Asp-Ala-Ile Phe-Thr-Arg-Ser-Phe-Arg-Lys-C MeVal-Leu-
Gly-Gln-Leu-Ser-Ala-Arg-Lys Leu-Leu-Gln-Asp-Ile-Leu-
Asn-Arg-NH2 is conducted in a stepwise manner using a
Beckman*990 Peptide Synthesizer on an MBHA resin as
generally described in Vale et al~ U.S. Patent No;
4,292,313. The peptide is judged to be substantially
pure using TLC and HPLC.
EXAMPLE XVIII
The synthesis of ~D-NMA2, CaMeTyr10,
caMevall3, caMeLeU2~, N1e27, Asn28]-hGRF(1-29)~
NH2 having the formula: H-Tyr-D-NMA-Asp-Ala-Ile-Phe-
Thr-Asn-Ser-CaMeTyr-Arg-Lys-CaMeVal-Leu-Gly-Gln-Leu-
Ser-Ala-Arq-Lys-CaMeLeu-Leu-Gln-Asp-Ile-Nle-Asn-Arg-
NH2 is conducted in a stepwise manner using a Beckman*
990 Peptide Synthesizer on an MBHA resin as generally
described in Vale et al. U.S. Patent No. 4,292,313. The
peptide is judged to be substantially pure using TLC and
HPLC.
EXAMPLE XIX
The synthesis of ~CaMePhel, D-N~A ,
CaMeTyr10~ CaMeIlel3, Val27~-rGRF(1-29)-NH2
having the formular H-CaMePhe-D-NMA-Asp-Ala-Ile-Phe-
Thr-Ser-Ser-C MeTyr-Arg-Arg-CaMeIle-Leu-Gly-Gln-Leu-
Tyr-Ala-Arg-Lys-Leu-Leu-His-Glu--Ile-Val-Asn-Arg-NH2 is
conducted in a stepwise manner using a Beckman*390
Peptide Synthesizer on an MBHA resin as in Example I.
The peptide is judged to be substantially pure using TLC
and HPLC.
EXAMPLE XX
The synthesis of [desaminoD-Met , D-NMA ,
aM T rl caMeVall3, CaMeAla , Asn 3
* trade-mark
- 20 -
hGRF(1-44~-NH2 having the formula:
desNH2-D-Met~D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-
CaMeTyr-Arg-Lys-CaMeVal-Leu-Gly-Gln-Leu-Ser-CaMeAla-
Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-NH~ is
5 conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as generally
described in Vale et al. U,S. Patent NoO 4,292,313. The
peptide is judged to be substantially pure using TLC and
HPLC.
EXAMPLE XXI
The synthesis of [NaMeHis , D-NMA , CaMeVall3-
Nle27]-hGRF(1-29)-NH2 having the formula: NaMeHis-
D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-C MeVal-
Leu-Gly-Gln-I.eu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-
Ser-Arg-NH2 is conducted in a stepwise manner using a
Beckman*990 Peptide Synthesizer on an MBHA resin as
generally described in Vale et al. U.S. Patent No.
4,232,313. The peptide is judged to be substantially
pure using TLC and HPLC.
EXAMPLE XXII
The synthesis of the hGRF analog fragment,
lF Tyrl D-NMA2, CaMeTyr10~ CaMeAla
Leu27, Asn28]-hGRF(1-32)-NH2 having the formula:
For-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-CaMeTyr-Arg-
Lys-Val-Leu-Gly-Gln-Leu-Ser-CaMeAla-Arg-Lys-Leu-Leu-Gln-
Asp-Ile-Leu-Asn-Arg~Gln-Gln-Gly-NH2 i5 conducted in a
stepwise manner using a Beckman*990 Peptide 5ynthesi2er
on an MBHA resin as in Example I. This analog is judged
to be substantially pure using TLC and HPLC.
EXAMPLE XXIII
The synthesis of lD-NMA , Lysl2, CaMeIlel3,
CaMeAlal9, Nle271~rGR~(1-29)-NH2, having the
formula: H-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-
Arg-Lys-CaMeIle-Leu-Gly-Gln-Leu-Tyr-CaMeAla-Arg-Lys-
Leu-Leu-His-Glu-Ile-Nle-Asn-Arg-NH2 is conducted in a
stepwise manner using a Beckman*990 Peptide Synthesizer
on an MBHA rlesin as in Example I. The peptide is judged
` to be substantially pure using TLC and HPLC.
.
*trade-mark
r
- 21 -
EXAMPLE XXIV
The synthesis of the hGRF analog fragment
[D-NM~, Argl21 CaMeLeu22, Ile27]-hGRF(1-29)-NH2
having the formula: H-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-
Asn-Ser-Tyr-Arg-Arg-Val-Leu G:Ly-Gln-Leu-Ser-Ala-Arg-
Lys-CaMeLeu-Leu-Gln-Asp-Ile-I:Le-Ser-Arg-NH2 is
conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as in Example I.
The peptide is judged to be substantially pure using TLC
and HPLC.
EXAMPLE XXV
The synthesis of [D-Phel, D-NMA2 CaMeVall3
Ala , C MeLeu , D-Met 7]-hGRF(1-29)-NH2
having the formula: ~I-D-Phe-D-NMA-Asp-Ala-Ile-Phe-Thr-
Asn-Ser-Tyr-Arg-Lys-CaMeVal-Leu-Ala-Gln-Leu-Ser-Ala-
Arg-Lys-CaMeLeu-Leu-Gln-Asp-Ile-D-Met-Ser-Arg-NH2 is
conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as in Example I.
This analog is judged to be substantially pure using TLC
and HPLC.
EXAMPLE XXVI -
The synthesis of lD-NMA2, D-Arg~lCaMeLeu22]
-hGRF(1-32)-NH2having the formula: H-Tyr-D-NMA-Asp
-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-
Ser-~la-Arg-D~Arg-CaMeLeu-Leu-Gln-Asp-Ile-Met-Ser Arg-
Gln-Gln-Gly-NH2 is conducted in a stepwise manner
using a Beckman*990 Peptide Synthesizer on an MBHA resin
as in Example I. This analog is judged to be
substantially pure using TLC and HPLC.
EXAMPLE XXVII
The synthesis of [desaminoHisl, D-NMA~
Lys , Asp ]-rGRF(1-29)-NH2 having the formula:
desNH2His-D-NMA-Asp-Ala-Ile-Phe-Thr-Lys-Ser-Tyr-Arg-Arg-
Ile-L~u-Gly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu Leu-His-Asp-Ile-
Met-Asn-Arg-NH2 is conducted in a stepwise manner
using a Beckman*990 Peptide Synthesizer on an MBHA resin
* trade-mark
,~
~2'~
- 22 -
as in Example I. The peptide is judged to be
substantially pure using TLC and HPLC.
EXAMPLE XXVIII
The synthesis of [Ac-D-Hisl, D-NMA2,
Arg , C MeTyr10, Nle27]-rGRF(1-29)-NH having
the formula: Ac-D-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Arg-Ser-
CaMeTyr-Arg-Arg-Ile-Leu Gly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu-
Leu-His-Glu-Ile-Nle-Asn-Arg-NE12 is conducted in a
stepwise manner using a Beckman*990 Peptide Synthesizer
on an MBHA resin, in the manner generally described in
Example I. The peptide is judged to be substantially
pure using TLC and HPLC.
EXAMPLE XXIX
The synthesis of lD-Ala2, D-Asp3,
15 CaMeTyr10, CaMeAlal9, CaMeLeu22, Leu27]_
hGRF(1-32)-NH2 having the formula: H-Tyr-D-Ala-D-Asp-
Ala-Ile-Phe-Thr-Asn-Ser-CaMeTyr-Arg-Lys-Val-Leu-Gly-Gln-
Leu-Ser-CaMeAla-Arg-Lys-CaMeLeu-1eu-Gln-Asp-Ile-Leu-
Ser-Arg-Gln-Gln-Gly-N~2 is conducted in a stepwise
manner using a Beckman*990 Peptide Synthesizer on an
MBHA resin as in Example I~ This analog is judged to be
substantially pure using TLC and HPLC.
EXAMPI.E XXX
The synthesis of ID-Tyrl, D-NMA2, D-Asp3,
25 Lys8 CaMe-D-Tyr10, Alal5, D-Met27]-hGRF(1-29~-NH2
having the formula: H-D-Tyr-D-NMA-D-Asp-Ala-Ile-Phe-Thr-
Lys-Ser-CaMe-D-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-
Arg-Lys-Leu-Leu-Gln-P.sp-Ile-D-Met-Ser-Arg-NH2 is
conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as in Example I.
This analog is judged to be substantially puxe using TLC
and HPLC.
EXAMPLE XXXI
The synthesis of [D-Hisl, D-NMA2, Arg~,
Leul3, CaMeAlal9, Nle273-rGRF(1-32)-NH~ having
the formula: H-D-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Arg-
,',: Ser-Tyr-Arg-Arg-Leu-Leu-Gly-Gln-Leu-Tyx-CaMeAla-Arg-
- trade-mark
~, ,
~3-~ 2 ~
- 23
Lys Leu-Leu-His-Glu-Ile-Nle-Asn-Arg-Gln-Gln-Gly-NH2 is
conducted in a stepwise manner using a Beckman*990
Peptide Synthesi~er on an MBHA resin, in the manner
generally described in Example I. The peptide is judged
to be substantially pure using TLC and HPLC.
EXAMPLE XXXII
The synthesis of a rGRF analog fragment i.e.
~desaminoTyrl, CaMeLeu22]-rGRF(1-29)-NH2 having
the formula: desNH2Tyr-Ala-Asp-Ala-Ile-Phe-Thr-
10 Ser-Ser-l~rr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-Lys-
CaMeLeu-Leu-His-Glu-Ile-Met-Asn-Arg-NH2 is conducted
in a stepwise manner using a Beckman*990 Peptide
Synthesiæer on an MBHA resin as in Example I. The
peptide is ~udged to be substantially pure using TLC and
HPLC.
EXAMPLE XXXIII
The synthesis o~ [Ac-D-Tyrl, D-NMA ,
C MeTyr , C MeVal , C MeAla
CaMeLeu22, Nle27]-hGRF(1-29)-NH2 having the
formula: Ac-D-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-
CaMeTyr-Arg-Lys-C~aMeVal-Leu-Gly-Gln-Leu-Ser-CaMeAla-
Arg-Lys-CaMeLeu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-NH2 is
conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as generally
2~ described in Vale et al. U.S. Patent No. 4,292,313. The
peptide is judged to be substantially pure using TLC and
HPLC.
EXAMPLE XXXIV
The synthesis of [CaMeLeul, D-NMA2,
Glu , CaMeAlal9, Glu25, Ile273-rGRF(1_29)_
NH2having the formula: H-CaMeLeu-D-NMA-Asp-Ala-Ile-
Phe-Thr-Glu-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-
CaMeAla-Arg-Lys-Leu-Leu-His-Glu-Ile-Ile-Asn-Arg-NH2
is conducted in a stepwise manner using a Beckman 990
Peptide Synthesizer on an MBHA resin as in Example I~
The peptide is judged to be substantially pure using TLC
and HPLC.
* trade-mark
.. , .. ,:
3 ~ 2 F~ J ~
- 24 -
EXAMPLE XXXV
The synthesis of [For-D-Tyrl, D-MMA ,
caM vall3 caMeAlal9, ~rg ~l r caMeLe~l ~
Asn28]-hGRF(1-29)-N~2 having the formula:
For-~-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys
CaMeVal-Leu-Gly-Gln-Leu-Ser-CaMeAla-Arg-Arg-CaMeLeu-
Leu-Gln-Asp-Ile-Met-Asn-Arg-NH2 is conducted in a
stepwise manner using a Beckman*990 Peptide Synthesizer
on an MBHA resin as generally described in Vale et al.
U.S. Patent No. 4,292,313. The peptide is judged to be
substantially pure using TLC and HPLC.
EXAMPLE XXXVI
The synthesis of lNMA2, CaMeVall3, Nle27]-
hGRF(1-29)-NH2 having the formula~ Tyr-NMA-Asp-
Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-CaMeVal-Leu-Gly-Gln-
Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-NH2
is conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as generally
described in Vale et al. U.S. Patent No. 4,292,313. The
peptide is judged to be substantially pure using TLC and
HPLC. The acetate salt is then prepared by dissolving
the peptide in water and adding lN acetic acid. The
resulting solution is lyophilized to yield the acetate
salt.
EXAMPLE XXXVII
The synthesis of the hGRF analog lD-NM~,
Arg8~ CaMeAlal9, CaMeLeU22Nle27~-hGRF(l-32)-
NH2 having the formulao H-Tyr-D~NMA-Asp-Ala-Ile-Phe-
Thr-Arg-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu Ser-C MeAla-
Arg-Lys-CaMeLeu-Leu-Gln-Asp-Ile-Nle-Ser-Arg-Gln-Gln-Gly-
-- NH2 is conducted in a stepwise manner using a Beckman*
9gO Peptide Synthesizer on an MBHA resin as in Example
I~ This analog is judged to be substantially p~re using
TLC and HPLC.
EXAMPLE XXXVIII
The synthesis of [Lys8, Arg21, Nle27]-
rGRF(1-29)-NH2, having the formula: H-~is-Ala-~sp-
* trade-mark
. ~ -
~ 3 ~
- 25 -
Ala-Ile-Phe-Thr-Lys-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-
I'yr-Ala-Arg-Arg-Leu-Leu-His-GluYGw~-Nle Asn-Arg-NH2 is
conducted in a stepwise manner using a Beckman*990
Peptide Synthesizer on an MBHA resin as in Example I.
The peptide is judged to be substantially pure using TLC
and HPLC.
EXAMPLE XXXIX
The synthesis of the hGRF analog [D-NMA2,
CaM Vall3 CaMeAlal9, CaMeLeu , Nle
Asn28]-hGRF(1-29)-NH2 having the formula: H-Tyr-D-
NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-C MeVal-
Leu-Gly-Gln-Leu-Ser CaMeAla-Arg-Lys-CaMeLeu-Leu-Gln-
Asp-Ile-Nle-Asn-Arg-NH2 is conducted in a stepwise
manner using a Beckman*990 Peptide Synthesizer on an
1~ MBHA resin as in Example I. The peptide is judged to be
substantially pure using TLC and HPLC.
EXAMPLE XL
The synthesis of [D-Ala2, D-Lys 1, Nle27]-
hGRF(1-29)-NH2 having the formula:
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-
Leu-Gly-Gln-Leu-Ser-Ala-Arg-D-Lys-Leu-Leu-Gln-Glu-Ile-
Nle-Ser-Arg-~H2 is conducted in a stepwise manner
using a Beckman 990 Peptide Synthesizer on an MBHA resin
as in Example I. The peptide is judged to be substanti-
ally pure using TLC and HPLC.
EXAMPLE XLI
The synthesis of [Metl, CaMeAlal9,
Arg21, Nle27]-rGRF~1-29)-NH2 having the formula:
H-Met-Ala-Asp-Ala-Ile~Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-
- 30 Gly-Gln-Leu-Tyr-CaMeAla-Arg-Arg-Leu-Leu-His-Glu-Ile-Nle-
Asn-Arg-NH2 is conducted in a stepwise manner using a
Beckman*990 Peptide Synthesizer on an MBHA resin as in
Example I. The peptide is judged to be substantially
pure using TLC and HPLC.
3~ * trade-mark
. ..
7 ~ ~
- 26
EX~MPLE XLII
The synthesis of ~pCl-Phel, D-NMA2,
C MeTyrl0, CaMeAl~l9~ Arg21~ Nle27] rGRF(l 43) o
having the formula: H-pCl-Phe D-NMA-Asp-Ala-Ile-Phe-Thr-
Ser-Ser-CaMeTyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-
CaMeAla-Arg-Arg-Leu-Leu-His-Asp-Ile-Nle-Asn-Arg-Gln-
Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Arg-Ser-Arg-Phe-Asn-
OH is conducted in a stepwise manner using a Beckman 990
Peptide Synthesizer on a chloromethylated resin as in
Example III. The peptide is judged to be substantially
pure using TLC and HPLC.
The synthetic peptides prepared in the Examples
are compared with synthetic hpGRF(1-40)-OH in in vitro
assays and are found to exhibit generally greater
potencies for the secretion of GH and similar intrinsic
activities. All of these synthetic peptides are
considered to be biologically active and potentially
useful for stimulating the release of GH by the
pituitary.
To determine the relative effectiveness of
certain representative synthe~ic pep*ides to promote the
release of growth hormone, in vitro assays are carried
out using synthetic hpG~F(1-40)-OH as a standard in
side-by-side comparison with equimolar concentrations of
the representative analogs which have been synthesized.
Cultures are used which include cells of rat pituitary
glands removed some three to five days previously. Such
cultures are considered optimal for the secretion of
growth hormone and are used for the comparative testingr
in the general manner described in Vale et al.
Endocrinology, 91, 562-572 (1972) and as more
particularly describ~d in Vale et al. Endocrinology,
112, 1553-1555 (1983). Incubation with the substance to
be tested is carried out for 3 to 4 hours, and aliquots
of the culture medium are removed and processed to
measure their contents in immunoreactive GH(ir GH) by a
well-characterized radioimmunoassay.
5~ * trade-mark
~ 3~7~
- 27 -
The results Or this comparative testing for
equimolar concentrations are shown in Table I.
TABLE I
Peptide Comparison
hGRF~1-40)-OH
(standard for this test) 100
[NaMeTyrl Asp8 Alal5 Nle27 192
Asn 8]_ hGRF~1-29)-NH2
[NaMeTyrl Lys8 Alal5 Nle27 556
Asn 81-hGRF(1-29)-NH2.
[N MeTyrl~ D_Lys21 Nle271 172
-hGRF(1-29)-N~ .
[NaMeTyr~ D-Tyrl~, D-Lys21, Nle27]- 40%
hGRF(1-29)-NH2.
In addition to the in vitro tests for secretion
of growth hormone, in vivo experiments inject the
synthetic peptides intravenously into urethane-
anesthetized male rats and determine that they suppress
spontaneous GH secretion without abolishing the response
to exogenous GRF. Blood samples are taken immediately
prior to, and 10, 30 and 60 minutes after injections,
and GH levels in blood are measured by radioimmunoassay.
This in vivo testing of these synthetic peptides shows
that each surprisingly has far greater biological
potency than that exhibited by hpGRF(1-40)-OH. These
synthetic GRF analogs have substantially longer duration
of effectiveness, which is shown in blood levels of
pituitary GH when measured at both 30 and 60 min. after
IV injection. Other known GRF in vivo tests that are
known to be effective to detect secretion of GH are used
to confirm these results. Dosages between about 500
nanograms and about 50 micrograms of these peptides per
Rg. of body weight are considered to be effective in
causing GH secretion.
Such synthetic hGRF analogs and possibly rG~F
analogs should be useful for human applications in which
- 28 -
a physician wishes to elevate GH production. S~imulation
o~ GH secretion by such analogs is of interest in
patients with complete or relative GH deficiency caused
by underproduction of endogenous GRF. Furthermore, it
is probable that increased GH secretion and its attendant
increase in growth could be obtained in humans or animals
with normal GH levels. Moreover, administration should
alter body fat content and modify other GH-dependent
metabolic, immunologic and developmental processes~ For
example, these analogs may be useful as a means of
stimulating anabolic processe~; in human beings under
circumstances such as following the incurring of burns.
As another example, these analogs may be administered to
commercial warm-blooded animals, such as chickens,
turkeys, pigs, goats, cattle and sheep, and may be used
in aquiculture for raising fish and other cold-blooded
marine animals, e.g. sea turtles and eels, and
amphibians, to accelerate growth and increase the ratio
of protein to fat gained by feeding effective amounts of
the peptides.
For administration to humans, these synthetic
peptides should have a purity of at least about 93~ and
preferably at least 98~. Purity, for purposes of this
applicationy refers to the intended peptide constituting
the stated weight % of all peptides and peptide
fragments present. For the administration of such
synthetic peptides to commercial and other animals in
order to promote growth and reduce fat contentt a purity
as low as about 5%, or even as low as 0.01%, may be
acceptable.
These synthetic peptides or the nontoxic salts
thereof, combined with a pharmaceutically or
veterinarily acceptable carrier to form a pharmaceutical
composition, may be administered to animals, including
humans, either intravenously, subcutaneously,
intramuscularly, percutaneously, e.g. intranasally or
r~
-- 29 ~
even orally. The administration may be employed by a
physician to stimulate the release of GH where the host
being treated requires such therapeutic treatment. The
required dosage will vary with the particular condition
being treated, with the severity of the condition and
with the duration of desired treatment.
Such peptides are often administered in the
form of nontoxic salts~ such as acid addition salts or
metal complexes, e.g., with zinc, iron or the like
(which are considered as salt!; for purposes of this
application). Illustrative of such acid addition salts
are hydrochloride, hydrobromide, sulphate, phosphate,
maleate, acetate, citrate, benzoate, succinate, malate,
ascorbate, tartrate and the like. If the active
ingredient is to be orally administered in tablet form,
the tablet may contain a binder, such as tragacanth,
corn starch or gelatin; a disintegrating agent, such as
alginic acid; and a lubricant, such as magnesium
stearate. If administration in liquid form is desired,
sweetening and/or flavoring may be used, and intravenous
administration in isotonic saline, phosphate buffer
solutions or the like may be effected.
The peptides should be administered to humans
under the guidance of a physician, and pharmaceutical
compositions will usually contain the peptide in
conjunction with a conventional, solid or liquid,
pharmaceutically-acceptable carrier. Usually, the
parenteral dosage will be from about 0.01 to about 1
microgram of the peptide per kilogram of the body weight
of the host.
Althou~h the invention has been described with
regard to its preferred embodiments, which constitute
the best mode presently known to the inventors t it
should be understood that various changes and
modifications as would be obvious to one having the
ordinary skill in this art may be made without departing
~3~,7~
- 30 -
from the scope of the invention which is set forth in
the claims appended hereto. For example, modifications
in the peptide chain, particularly deletions beginning
at the carboxyl terminus of the peptide and extending to
about position-29, can be made in accordance with the
known experimental practises to date to create peptides
or peptide fragments that retain all or very substantial
portions of the biological potency of the peptide, and
such peptides are considered as being within the scope
of the invention. Moreover, additions may be made to
either terminus, or to both terminals, and/or generally
equivalent residues can be substituted for naturally
occurring residues, as is well-known in the overall art
of peptide chemistryy to produce other analogs having at
least a substantial portion of the potency of the
claimed polypeptide without deviating from the scope of
the invention. ~oreover, modifications may be made to
the preferred -NH2 group at the C-terminus in
accordance with the state of this art today, for
example, the carboxyl moiety of the amino acid residue
at the C-terminus can be the radical
-COOR,-CRO,-CONHNHR,-CONtR)(R') or -CH2OR~ with R and
R' being lower alkyl, fluoro lower alkyl or hydrogen,
without deviating from the invention for such
modifications result in equivalent synthetic peptides.
Various features of the invention are emphasized
in the claims which followO
